Pfizer (NYSE:PFE) Stock Price Down 2.3% – Should You Sell?

Pfizer Inc. (NYSE:PFE) traded down 2.3% during trading on Tuesday. The company traded as low as $29.89 and last traded at $29.9750. Approximately 52,648,660 shares were traded during trading, an increase of 33% from the average session volume of 39,723,945 shares. The stock had previously closed at $30.67.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported adjusted earnings of $0.87 per share and revenue of $16.58 billion, exceeding analyst estimates. It raised its 2026 revenue outlook to $62 billion–$64 billion, citing strong performance and execution. Reuters: Pfizer raises 2026 forecast
• Positive Sentiment: Growth in newer and acquired medicines helped offset weakness elsewhere: launched products grew 32%, with Eliquis, Padcev and Lorbrena among the drivers. This supports Pfizer’s effort to build growth beyond its pandemic-era products. Blockonomi: Pfizer Q3 revenue and launched products
• Neutral Sentiment: Pfizer appointed longtime company finance executive Cecile Guegan as CFO, effective November 1. The appointment offers continuity, though the reports provided no expected financial impact. CNBC: Pfizer hikes outlook and names new CFO
• Negative Sentiment: Revenue was essentially flat year over year as COVID product sales continued to contract: Paxlovid revenue fell 63% and Comirnaty sales dropped 29%. Those declines may temper confidence in the durability of Pfizer’s growth, despite the stronger non-COVID portfolio. The Motley Fool: Eliquis gains and COVID sales declines

Analysts Set New Price Targets

Several analysts have weighed in on the company. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Bank of America lowered their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Cantor Fitzgerald increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Five analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.65.

Pfizer Trading Down 2.3%

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock’s fifty day simple moving average is $28.60 and its 200-day simple moving average is $26.82. The firm has a market cap of $170.85 billion, a PE ratio of 39.44, a PEG ratio of 2.00 and a beta of 0.32.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13. The company had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. Pfizer’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the business earned $0.87 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.7%. Pfizer’s dividend payout ratio is presently 226.32%.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Pictet Asset Management Holding SA raised its stake in Pfizer by 62.8% in the 3rd quarter. Pictet Asset Management Holding SA now owns 4,721,719 shares of the biopharmaceutical company’s stock valued at $134,667,000 after acquiring an additional 1,820,944 shares during the period. Leelyn Smith LLC increased its stake in shares of Pfizer by 3.9% in the 3rd quarter. Leelyn Smith LLC now owns 128,235 shares of the biopharmaceutical company’s stock valued at $3,657,000 after purchasing an additional 4,851 shares during the last quarter. Verus Capital Partners LLC grew its holdings in Pfizer by 5.1% during the 3rd quarter. Verus Capital Partners LLC now owns 16,716 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 805 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co bought a new position in shares of Pfizer during the third quarter valued at $221,000. Finally, Pathway Financial Advisers LLC lifted its holdings in Pfizer by 17.3% during the 3rd quarter. Pathway Financial Advisers LLC now owns 67,908 shares of the biopharmaceutical company’s stock worth $1,937,000 after buying an additional 10,005 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.